Cathay Biotech Inc
SSE:688065
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
C
|
Cathay Biotech Inc
SSE:688065
|
39.2B CNY |
Loading...
|
|
| US |
|
Sherwin-Williams Co
NYSE:SHW
|
91.1B USD |
Loading...
|
|
| US |
|
Ecolab Inc
NYSE:ECL
|
84.6B USD |
Loading...
|
|
| JP |
|
Shin-Etsu Chemical Co Ltd
TSE:4063
|
10.3T JPY |
Loading...
|
|
| CN |
|
Wanhua Chemical Group Co Ltd
SSE:600309
|
269.1B CNY |
Loading...
|
|
| CH |
|
Givaudan SA
SIX:GIVN
|
28.6B CHF |
Loading...
|
|
| US |
|
PPG Industries Inc
NYSE:PPG
|
29.4B USD |
Loading...
|
|
| DK |
|
Novozymes A/S
CSE:NZYM B
|
165.6B DKK |
Loading...
|
|
| IN |
|
Asian Paints Ltd
NSE:ASIANPAINT
|
2.3T INR |
Loading...
|
|
| CH |
|
Sika AG
F:SIKA
|
19.9B EUR |
Loading...
|
|
| US |
|
International Flavors & Fragrances Inc
NYSE:IFF
|
21.1B USD |
Loading...
|
Market Distribution
| Min | -416 945.9% |
| 30th Percentile | -1.5% |
| Median | 3.5% |
| 70th Percentile | 8.9% |
| Max | 17 382.1% |
Other Profitability Ratios
Cathay Biotech Inc
Glance View
Cathay Biotech Inc. emerged from China's bustling metropolis of Shanghai, carving a niche in the realm of synthetic biology. Born in the late 1990s, the company set its sights on transforming the industrial landscape by harnessing the power of biomanufacturing. Cathay positioned itself as a leader in the production of long-chain diacid (LCDA) and bio-based polyamides, which are integral to a wide array of industries, including automotive, consumer electronics, and textiles. The company's core technology lies in advanced fermentation processes, where microorganisms are bioprocessed to produce these high-performance materials. These procedures not only reduce dependency on petrochemicals but also showcase the potential for sustainable innovations in industrial applications. Cathay Biotech monetizes its expertise by serving as a vital supplier for manufacturers worldwide, tapping into its patented technologies and scaling them to meet commercial demands. Its commitment to R&D has not only propelled the firm’s growth but also established long-term partnerships with key players across various sectors. Through its production facilities, Cathay has managed to fine-tune its microorganism strains and fermentation processes, leading to increased efficiencies and cost-effectiveness. This symbiotic relationship between innovation and commercialization at Cathay Biotech has allowed it to create a robust business model, drawing significant revenue from the sale of its bio-based products while consistently investing in technological advancements to expand its product portfolio.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Cathay Biotech Inc is 18.1%, which is above its 3-year median of 17.4%.
Over the last 3 years, Cathay Biotech Inc’s Net Margin has decreased from 25.1% to 18.1%. During this period, it reached a low of 14.4% on Sep 30, 2024 and a high of 25.1% on Sep 30, 2022.